drugset / Trial / NCT02897778

Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors

NCT02897778

Phase 1 Completed 30 enrolled Syndax Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the effect of entinostat on heart rate and other electrocardiogram (ECG) parameters. This study will also evaluate the safety and tolerability of entinostat, as well as pharmacokinetic and pharmacodynamic parameters.

Timeline

Start
2016-08-24
Primary completion
2017-03-13
Completion
2017-03-13

Drugs

EvaluationDrugModalityDoseRoute
Comparator Entinostat Small molecule 15 mg Oral